These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 39022386)

  • 1. Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants.
    Bril F; Kalavalapalli S; Lomonaco R; Frye R; Godinez Leiva E; Cusi K
    JHEP Rep; 2024 Jul; 6(7):101092. PubMed ID: 39022386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy.
    Xia M; Varmazyad M; Pla-Palacín I; Gavlock DC; DeBiasio R; LaRocca G; Reese C; Florentino RM; Faccioli LAP; Brown JA; Vernetti LA; Schurdak M; Stern AM; Gough A; Behari J; Soto-Gutierrez A; Taylor DL; Miedel MT
    Front Cell Dev Biol; 2024; 12():1423936. PubMed ID: 39324073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision Therapy.
    Xia M; Varmazyad M; Palacin IP; Gavlock DC; Debiasio R; LaRocca G; Reese C; Florentino R; Faccioli LAP; Brown JA; Vernetti LA; Schurdak ME; Stern AM; Gough A; Behari J; Soto-Gutierrez A; Taylor DL; Miedel M
    bioRxiv; 2024 May; ():. PubMed ID: 38712213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adipose Tissue Insulin Resistance Correlates with Disease Severity in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Cohort Study.
    Heldens A; Dupont E; Devisscher L; Buytaert M; Verhelst X; Raevens S; Van Vlierberghe H; Geerts A; De Bruyne R; Lefere S
    J Pediatr; 2024 Jun; 274():114171. PubMed ID: 38944185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of
    Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders.
    Xia MF; Ling Y; Bian H; Lin HD; Yan HM; Chang XX; Li XM; Ma H; Wang D; Zhang LS; Wang SS; Wu BJ; He WY; Zhao NQ; Gao X
    Aliment Pharmacol Ther; 2016 Mar; 43(5):631-42. PubMed ID: 26765961
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.
    Lavrado NC; Salles GF; Cardoso CRL; de França PHC; Melo MFDGG; Leite NC; Villela-Nogueira CA
    Liver Int; 2024 Apr; 44(4):1042-1050. PubMed ID: 38293718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PNPLA3 I148 M genetic variant in autoimmune hepatitis characterises advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related mortality.
    Azariadis K; Gatselis NK; Lyberopoulou A; Arvaniti P; Zachou K; Gabeta S; Dalekos GN
    J Transl Autoimmun; 2024 Dec; 9():100243. PubMed ID: 38974691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease.
    Kocas-Kilicarslan ZN; Cetin Z; Faccioli LAP; Motomura T; Amirneni S; Diaz-Aragon R; Florentino RM; Sun Y; Pla-Palacin I; Xia M; Miedel MT; Kurihara T; Hu Z; Ostrowska A; Wang Z; Constantine R; Li A; Taylor DL; Behari J; Soto-Gutierrez A; Tafaleng EN
    Gastro Hep Adv; 2024; 3(1):67-77. PubMed ID: 38292457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological Study on the Interaction between the
    Sato S; Iino C; Sasada T; Soma G; Furusawa K; Yoshida K; Sawada K; Mikami T; Nakaji S; Sakuraba H; Fukuda S
    Genes (Basel); 2024 Sep; 15(9):. PubMed ID: 39336763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activin A levels in metabolic dysfunction-associated steatotic liver disease associates with fibrosis and the PNPLA3 I148M variant.
    Jönsson C; Bergram M; Kechagias S; Nasr P; Ekstedt M
    Scand J Gastroenterol; 2024 Jun; 59(6):737-741. PubMed ID: 38563432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients.
    Gavril OI; Arhire LI; Gavril RS; Zota MI; Gherasim A; Nita O; Drugescu A; Oprescu AC; Esanu IM; Mitu F; Graur M; Mihalache L
    Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833467
    [No Abstract]   [Full Text] [Related]  

  • 15. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
    Rametta R; Ruscica M; Dongiovanni P; Macchi C; Fracanzani AL; Steffani L; Fargion S; Magni P; Valenti L
    Eur J Clin Invest; 2014 Jul; 44(7):627-33. PubMed ID: 24828988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
    Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
    Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
    Karamfilova V; Gateva A; Assyov Y; Alexiev A; Savov A; Yaneva N; Ivanova I; Ivanova-Boyanova R; Ivanova R; Vlahova Z; Mateva L; Kamenov Z
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):433-438. PubMed ID: 31826069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.